Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer

Swedish biotech firm Aqilion has acquired a phase-1 ready candidate from Leo Pharma, and the firm is aiming to address a high unmet medical need in the form of the inflammation disease, eosinophilic esophagitis. Through the deal, Leo Pharma also becomes a shareholder of Aqilion.
Leo Pharma sells phase-I ready drug candidate and becomes a shareholder in Swedish buyer Aqilion | Photo: Leo Pharma / PR
Leo Pharma sells phase-I ready drug candidate and becomes a shareholder in Swedish buyer Aqilion | Photo: Leo Pharma / PR
by albert rønning-andersson, translated by daniel pedersen

International attention continues to be fixed on Leo Pharma, which saw its CEO Catherine Mazzacco step down with immediate effect last week.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading